DK3653644T5 - Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft - Google Patents

Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft Download PDF

Info

Publication number
DK3653644T5
DK3653644T5 DK19205321.3T DK19205321T DK3653644T5 DK 3653644 T5 DK3653644 T5 DK 3653644T5 DK 19205321 T DK19205321 T DK 19205321T DK 3653644 T5 DK3653644 T5 DK 3653644T5
Authority
DK
Denmark
Prior art keywords
cancer
cachesia
gdf
treatment
monoclonal antibodies
Prior art date
Application number
DK19205321.3T
Other languages
Danish (da)
English (en)
Other versions
DK3653644T3 (da
Inventor
Jörg Wischhusen
Markus Junker
Tina Schäfer
Dirk Pühringer
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Application granted granted Critical
Publication of DK3653644T3 publication Critical patent/DK3653644T3/da
Publication of DK3653644T5 publication Critical patent/DK3653644T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
DK19205321.3T 2014-03-26 2015-03-26 Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft DK3653644T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
EP15712629.3A EP3122775B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Publications (2)

Publication Number Publication Date
DK3653644T3 DK3653644T3 (da) 2023-12-18
DK3653644T5 true DK3653644T5 (da) 2024-08-26

Family

ID=52745885

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15712629.3T DK3122775T3 (da) 2014-03-26 2015-03-26 Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
DK19205321.3T DK3653644T5 (da) 2014-03-26 2015-03-26 Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15712629.3T DK3122775T3 (da) 2014-03-26 2015-03-26 Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer

Country Status (22)

Country Link
US (5) US20170204174A1 (OSRAM)
EP (3) EP4316596A3 (OSRAM)
JP (3) JP6865585B2 (OSRAM)
KR (1) KR102520978B1 (OSRAM)
CN (1) CN106536553B (OSRAM)
AU (2) AU2015238264B2 (OSRAM)
BR (1) BR122023027559A2 (OSRAM)
CY (1) CY1122456T1 (OSRAM)
DK (2) DK3122775T3 (OSRAM)
ES (2) ES2763859T3 (OSRAM)
FI (1) FI3653644T3 (OSRAM)
HR (2) HRP20231514T1 (OSRAM)
HU (2) HUE064573T2 (OSRAM)
IL (2) IL248038B (OSRAM)
LT (2) LT3122775T (OSRAM)
NZ (1) NZ724649A (OSRAM)
PL (2) PL3653644T3 (OSRAM)
PT (2) PT3653644T (OSRAM)
RS (1) RS59700B1 (OSRAM)
SI (1) SI3122775T1 (OSRAM)
SM (1) SMT202000064T1 (OSRAM)
WO (1) WO2015144855A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
US20170306008A1 (en) 2014-09-25 2017-10-26 Aveo Pharmaceuticals, Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
AU2016333538B2 (en) * 2015-10-02 2022-03-31 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EA201890850A1 (ru) * 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
JP7138567B2 (ja) * 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
JP7059494B2 (ja) * 2016-07-06 2022-04-26 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門を通過するヒト化抗体及びその使用
US20190234935A1 (en) * 2016-10-12 2019-08-01 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
EP3551214B1 (en) * 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
PE20211412A1 (es) * 2018-08-20 2021-08-02 Pfizer Anticuerpos anti-gdf15, composiciones y metodos de uso
IL302646A (en) 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
PT1179067E (pt) 1999-05-17 2007-01-31 Biopharm G Biotechnolo Entwi V Propriedades neuroprotectoras de gdf-15, um membro da superfamília de tgf-beta
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
PT2311873T (pt) * 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
ES2555956T3 (es) 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
JP2010536717A (ja) * 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
CN101896192A (zh) * 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
UA103499C2 (ru) 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
SI2900263T1 (sl) * 2012-09-26 2019-09-30 Julius-Maximilians-Universitaet Wuerzburg Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (gdf-15)
CN105073133B (zh) * 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro

Also Published As

Publication number Publication date
AU2015238264B2 (en) 2020-09-03
CN106536553A (zh) 2017-03-22
LT3122775T (lt) 2020-02-10
EP3653644A1 (en) 2020-05-20
KR20160139005A (ko) 2016-12-06
HRP20200034T1 (hr) 2020-03-20
NZ724649A (en) 2022-07-01
FI3653644T3 (fi) 2023-12-12
DK3122775T3 (da) 2020-02-03
PT3653644T (pt) 2023-12-19
CY1122456T1 (el) 2021-01-27
JP2021119138A (ja) 2021-08-12
PL3122775T3 (pl) 2020-05-18
US20200308264A1 (en) 2020-10-01
WO2015144855A1 (en) 2015-10-01
PT3122775T (pt) 2019-12-26
US20200308265A1 (en) 2020-10-01
IL248038B (en) 2020-08-31
PL3653644T3 (pl) 2024-03-04
EP3653644B1 (en) 2023-11-15
EP4316596A3 (en) 2024-04-17
JP2023098966A (ja) 2023-07-11
AU2020260440B2 (en) 2024-03-21
KR102520978B1 (ko) 2023-04-11
SMT202000064T1 (it) 2020-03-13
HUE047398T2 (hu) 2020-04-28
LT3653644T (lt) 2024-01-25
BR112016022013A2 (pt) 2017-10-31
RS59700B1 (sr) 2020-01-31
SI3122775T1 (sl) 2020-02-28
HRP20231514T1 (hr) 2024-03-01
CN106536553B (zh) 2021-03-12
DK3653644T3 (da) 2023-12-18
ES2965626T3 (es) 2024-04-16
JP6865585B2 (ja) 2021-04-28
CA2943694A1 (en) 2015-10-01
AU2020260440A1 (en) 2020-11-26
EP4316596A2 (en) 2024-02-07
IL276405A (en) 2020-09-30
AU2015238264A1 (en) 2016-10-20
US20170204174A1 (en) 2017-07-20
BR122023027559A2 (pt) 2024-01-30
EP3122775A1 (en) 2017-02-01
EP3122775B1 (en) 2019-11-13
US20230382987A1 (en) 2023-11-30
IL276405B (en) 2021-07-29
US11634482B2 (en) 2023-04-25
HUE064573T2 (hu) 2024-03-28
JP2017508475A (ja) 2017-03-30
US20180298091A1 (en) 2018-10-18
US11760795B2 (en) 2023-09-19
US10604565B2 (en) 2020-03-31
ES2763859T3 (es) 2020-06-01
JP7607498B2 (ja) 2024-12-27
IL248038A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
DK3653644T5 (da) Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft
IL272470A (en) Methods and materials for assessing and treating cancer
HUE053452T2 (hu) Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
DK3508502T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
EP3426686C0 (en) Humanized Anti-PACAP Antibodies and Their Uses
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3142751T3 (da) Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
IL270729A (en) Therapeutic anti-cd40 ligand antibodies
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
IL262588A (en) Humanized anti-basigin antibodies and the use thereof
IL258924A (en) Humanized anti-dkk2 antibody and uses thereof
IL282478A (en) Materials and methods for treating cancer
DK3349731T3 (da) Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft
DK3313528T3 (da) Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer
GB2524553C (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer